Wellspect
Wellspect, a leading name in the medical technology industry, is headquartered in Sweden (SE) and operates extensively across Europe and North America. Founded in 2014, the company has quickly established itself as a pioneer in innovative healthcare solutions, particularly in the fields of urology and continence care. Wellspect is renowned for its core products, including the LoFric range of intermittent catheters, which are distinguished by their unique hydrophilic coating that enhances comfort and reduces the risk of urinary tract infections. The company’s commitment to quality and patient-centric design has positioned it as a trusted partner in healthcare, achieving notable recognition for its contributions to improving patient outcomes. With a focus on research and development, Wellspect continues to lead the way in advancing medical technologies that empower individuals to manage their health with confidence.
DitchCarbon Score
How does Wellspect's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Wellspect's score of 55 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Wellspect's reported carbon emissions
In 2023, Wellspect AB reported total greenhouse gas emissions of approximately 25,442,000 kg CO2e for Scope 1, 154,000 kg CO2e for Scope 2, and about 22,500,000 kg CO2e for Scope 3 emissions. The Scope 3 emissions included significant contributions from purchased goods and services (approximately 133,554,000 kg CO2e) and upstream transportation and distribution (about 39,474,000 kg CO2e). Wellspect has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its value chain by 2045. The company has established near-term targets to reduce absolute Scope 1 and 2 emissions by 80% by 2030 from a 2021 baseline, and to cut Scope 3 emissions by 42% within the same timeframe. Furthermore, Wellspect aims for 74.9% of its suppliers, based on emissions, to have science-based targets by 2026. Long-term, Wellspect is committed to a 95% reduction in absolute Scope 1 and 2 emissions and a 90% reduction in Scope 3 emissions by 2045, both from a 2021 base year. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect the company's commitment to addressing climate change effectively. The emissions data for Wellspect is cascaded from its parent company, Wellspect HealthCare AB, which is part of the DENTSPLY SIRONA Inc. corporate family. This relationship underscores the company's integrated approach to sustainability and climate action within the healthcare equipment and supplies sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 23,931,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 1,295,000 | 000,000 | 000,000 |
| Scope 3 | 19,783,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Wellspect is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
